Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)
Clinical trial NCT03346070 · COMPLETED
Trial details
- NCT number
- NCT03346070
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-01
- Primary completion
- 2019-01-29
- Enrollment
- 207
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.